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Summary The pNR-2 mRNA is regulated by oestrogens in cell lines established from metastatic human
breast cancer cells. The levels of the pNR-2 and oestrogen receptor RNAs have been measured in 96 tumour
samples from patients undergoing surgery for breast cancer. Oestrogen receptor mRNA was detected in 90%
of the 60 primary breast tumour samples from patients not receiving endocrine therapy at the time of surgery,
whereas the pNR-2 RNA was detected in 57%. In primary tumours the expression of pNR-2 was entirely
dependent upon oestrogen receptor RNA expression. When the 60 primary tumours were considered, pNR-2
and oestrogen receptor mRNA levels were significantly correlated. There was no significant correlation for
pNR-2 positive tumours. pNR-2 mRNA levels were similar in tumours of pre- and post-menopausal patients
and were independent of tumour differentiation and nodal status. Oestrogen receptor and pNR-2 mRNA
levels were also measured in 21 tumour samples from patients receiving primary tamoxifen therapy. Eleven of
these had shown an objective response and a significantly larger number of tumours from these patients
contained pNR-2 mRNA than from patients who did not respond (X2=6.08, P<0.025).
Breast cancer is the commonest form of cancer in European
and American women. The growth of a proportion of breast
tumours is dependent on oestrogens and oestrogens stimulate
the proliferation of oestrogen receptor positive breast cancer
cells in culture (Lippman & Bolan, 1975).
The anti-oestrogen tamoxifen is currently the most widely
used first line therapy for breast cancer and there would be
considerable clinical advantage in accurate prediction of the
response of individual patients to this drug. Oestrogen recep-
tor status is of predictive value (McGuire et al., 1975) and
some groups have demonstrated the additional value of
measuring the level of the progesterone receptor which is
induced by oestrogen (Osborne et al., 1980). However, 20%
of patients whose tumours contain both steroid receptors do
not respond to endocrine therapy, and 10% of patients
whose tumours contain neither receptor do respond (Desom-
bre et al., 1980). Because receptor status does not predict
response to endocrine therapy with sufficient accuracy, oest-
rogen and progesterone receptor levels are frequently not
measured or tamoxifen is prescribed regardless of receptor
status.
The proliferation of two oestrogen receptor positive breast
cancer cell lines (MCF-7, Soule et al., 1973; and ZR 75,
Engel et al., 1978) is oestrogen responsive (Lippman &
Bolan, 1975; Darbre et al., 1984). Recently, oestrogen-
regulated RNAs have been isolated by differential screening
of cDNA libraries prepared from these cells (May & Westley,
1986, 1988; Westley & May, 1987). The pNR-2 RNA was
isolated from both cell lines and corresponds to the pS2
RNA identified by others (Masiakowski et al., 1982; Prud'
homme et al., 1985). It is regulated specifically by oestrogens
in the oestrogen responsive MCF-7, ZR 75, T47D (May &
Westley, 1988) and EFM-19 (Westley et al., 1989) cell lines
but is not detected in breast cancer cell lines that do not
respond to oestrogens. Thus the pNR-2 RNA is a candidate
marker of the oestrogen responsiveness of breast tumour
cells.
The sequence of the pNR-2/pS2 RNA (Jakowlew et al.,
1984; Prud'homme et al., 1985; our unpublished data) sug-
gests that it codes for a cysteine-rich protein with features
reminiscent of the growth factor IGF-I and recently it has
been reported to show homology to porcine pancreatic spas-
molytic polypeptide (Rio et al., 1988). It has also been dem-
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onstrated that the protein is secreted by MCF-7 cells (Nunez
et al., 1987).
In this study, the levels of the oestrogen receptor mRNA
and the pNR-2 mRNA have been measured in 96 breast
tumour samples. The pNR-2 mRNA was expressed only in a
subset of oestrogen receptor positive tumours and pNR-2
levels were associated with response to primary tamoxifen
therapy.
Materials and methods
Tumour samples
A total of 96 breast tumour samples were collected from
patients undergoing surgery for breast cancer and analysed.
Sixty samples were from primary tumours, resected from
women who had not previously received endocrine therapy;
these tumours comprised 55 ductal carcinomas, two lobular
carcinomas, two atypical medullary carcinomas and a mixed
tubular carcinoma. There were four samples from local recur-
rences, a ductal carcinoma from a woman who had received
tamoxifen therapy, two other ductal carcinomas and one
lobular carcinoma. Eleven axillary nodes containing meta-
static breast cancer were analysed, including three from
women who had already received endocrine therapy. Twenty
samples (18 ductal carcinomas, one mucinous ductal car-
cinoma and one primary squamous carcinoma) were from
tumours ofelderly post-menopausal patients resected because
of disease progression while on primary tamoxifen therapy
and a further sample was from the ductal carcinoma of a
woman who was responding to tamoxifen therapy. Fresh
tumour samples of between 0.3 and 1 g were stored in liquid
nitrogen. Adjacent areas of tumour were examined his-
tologically.
RNA extraction andhybridisation
Frozen tumour samples were pulverised using a mikro
dismembrator. RNA was then extracted by the lithium
chloride, urea method as described previously (Henry et al.,
1988). RNA yields varied between 40 and 940jig. The lymph
nodes gave the highest RNA yields. RNA samples (10fig)
were denatured, fractionated by electrophoresis through
denaturing agarose gels and transferred to nylon membranes.
The oestrogen receptor (Walter et al., 1985) and pNR-2
(May & Westley, 1987) cDNAs were subcloned into vectors
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which permit transcription of sensitive, radiolabelled antisense
RNA probes (Melton et al., 1984). Filters were initially hyb-
ridised with 10' c.p.m. ml-' of the oestrogen receptor probe
for 3 days at 65°C in a buffer that contained 50% fonnamide
(Melton et al., 1984). They were then washed in 0.1 x SSC,
0.1% SDS at 80°C and exposed to pre-flashed X-ray film for
various lengths of time. The hybridised radioactivity was
subsequently removed from the filters and they were rehyb-
ridised with i07c.p.m. ml-' of the pNR-2 probe exactly as
described for the oestrogen receptor probe.
Quantification ofthe oestrogen receptor andpNR-2 RNAs
The intensity of the autoradiographic signal produced by the
hybridisation to the RNA samples was analysed with a scan-
ning densitometer and the areas under the resultant peaks
were integrated. For each filter several autoradiographic
exposures of varying time were scanned twice each. Internal
standards were provided by 10-fold dilutions of MCF-7
RNA (10 jg, lLjg, 0.1 iLg and 0.01 jLg) which were electro-
phoresed and transferred to each filter; the tumour RNA
values were corrected relative to the values obtained for hyb-
ridisation to these different concentrations of MCF-7 RNA.
The level of oestrogen receptor mRNA present in 1 jig of
MCF-7 cell RNA was defined as 1 unit. pNR-2 mRNA is
approximately 200-fold more abundant than oestrogen recep-
tor mRNA in MCF-7 cells (May & Westley, 1986, 1987;
Walter et al., 1985), and hence the level of pNR-2 RNA in
I jig of total MCF-7 cell RNA was designated as 200 units.
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Figure 1 Hybridisation of pNR-2 and oestrogen receptor RNA
probes to Northern transfers of RNA from MCF-7 cells, primary
ductal carcinomas of breast, breast carcinoma lymph node meta-
stases and a uterus from a premenopausal women. Ten jig of total
RNA from each of the tissue samples and 10, 1, 0.1 or 0.01 jig of
total RNA from MCF-7 cells were separated by gel electro-
phoresis, transferred to Hybond-N membrane and hybridised with
the oestrogen receptor or pNR-2 RNA probes as described in the
Materials and methods. The autoradiograph was exposed for 14
days for the oestrogen receptor RNA and for 4 days for the
pNR-2 RNA. The length of the RNA is shown on the right in
kilobases. The numbers under the tumour samples refer to the
patient number.
DNA analysis
DNA was extracted from dismembrated tumour samples.
FivelLg of DNA extracted from 82 primary breast cancers
and nine breast cancer metastases from axillary lymph nodes
(of which seven corresponded to primary tumours also ex-
tracted) were digested with Eco RI, electrophoresed for 500
volt hours in an 0.8% agarose gel and transferred to nitrocel-
lulose membranes as described by Southern (1975). After
transfer, membranes were washed in 3 x SSC and baked under
vacuum for 2 h at 80°C.
The filters were first hybridised with I07 c.p.m. ml-' of
32P-labelled pNR-2 as described previously (Westley & May,
1984). Unbound probe was removed from the filters by serial
washes in 0.3 x SSC, 0.1% SDS at room temperature fol-
lowed by two washes over 2 h at 65°C in the same solution.
The filters were then exposed to pre-flashed X-ray film at
- 70°C for various lengths of time. To correct for varying
DNA loading and transfer, filters were washed for 30 min in
two changes of 0.03 M sodium hydroxide at room
temperature and then rehybridised with a 32P-labelled tubulin
probe. Probe hybridisation was quantified by scanning den-
sitometry of the autoradiographs and the ratio of pNR-2 to
tublin hybridisation was calculated.
Results
Detection ofpNR-2 RNA in breast tumour samples
pNR-2 and oestrogen receptor mRNA levels were measured in
the 96 tumour samples as described in Materials and
methods. Examples of the autoradiographs obtained with the
two probes are shown in Figure 1. Hybridisation to different
amounts of MCF-7 cell RNA is on the left of the figure.
Tumours 28 and 32 contained both RNAs; tumours 33, 34
and 35 contained low levels of oestrogen receptor RNA but no
detectable pNR-2 RNA and tumour 29 did not contain either
RNA. All three metastatic deposits from axillary lymph nodes
contained both the oestrogen receptor and pNR-2 RNAs.
RNA from the uterus of a premenopausal woman contained
high levels of the oestrogen receptor RNA but no pNR-2
RNA.
Of the 96 breast tumour samples analysed, 79 (83%) con-
tained oestrogen receptor RNA but only 53 (55%) contained
the pNR-2 RNA. The positive oestrogen receptor RNA levels
varied over a larger range (14,000-fold) than the positive pNR-
2 RNA levels (600-fold). Where present, the pNR-2 RNA was
generally more abundant than the oestrogen receptor RNA.
Dependence ofpNR-2 expression on expression ofthe oestrogen
receptor
Expression of the pNR-2 RNA has been related to the level
of the oestrogen receptor RNA in the 60 samples from
primary breast tumours of patients who had not received
pre-surgical endocrine therapy (Figure 2). Fifty-four tumours
(90%) contained oestrogen receptor mRNA and 34 tumours
(57%) contained pNR-2 mRNA. None of the primary
tumours that did not express oestrogen receptor messenger
RNA expressed pNR-2 mRNA and pNR-2 mRNA was
more likely to be present in tumours expressing higher levels
of oestrogen receptor mRNA (Figure 2). Only 25% of
tumours containing less than 1 unit of oestrogen receptor
mRNA expressed pNR-2 mRNA, whereas 75% of tumours
containing 1-10 units, 75% of those expressing 10-100 units
and 67% of those expressing in excess of 100 units of oest-
rogen receptor mRNA expressed the pNR-2 mRNA. Thus,
expression of the oestrogen-regulated pNR-2 RNA is depen-
dent upon and appears to be related to levels ofexpression of
the oestrogen receptor mRNA in primary breast tumours.
The levels of both RNAs in each tumour sample are
plotted in Figure 3. There was a significant correlation
between the levels of the oestrogen receptor and pNR-2
RNAs (Spearman's rank coefficient = 0.42, P<0.001) when
all 60 primary tumours were considered. There was, however,
no significant correlation between the levels of the two
mRNAs when the pNR-2 negative tumours were excluded
from the analysis.
Analysis ofthepNR-2 gene in breast tumour DNA
DNA samples from 82 primary breast carcinomas and nine
lymph node metastases were examined. Hybridisation of Eco
RI-digested DNA with nick translated pNR-2 DNA revealed
weak hybridisation to a fragment of approximately 9.0 kb
long and stronger hybridisation to a fragment of approx-
imately 2.8 kb (Figure 4), in agreement with other studies
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Figure 2 Oestrogen receptor mRNA levels in pNR-2 RNA
positive and negative primary breast tumours. Oestrogen receptor
RNA and pNR-2 RNA levels were measured as described in the
Materials and methods. The oestrogen receptor RNA level is
measured in units, 1 unit being equivalent to the amount of
oestrogen receptor RNA in 1 yg total MCF-7 RNA.
pNR-2 and tubulin DNA
pNR-2
-9.0 kb
-2.8 kb
tubulin
20 21 22 23 24 25 26 27 28
Tumour no.
Figure 4 Hybridisation of pNR-2 and tubulin probe to
Southern transfers of Eco RI digested DNA prepared from
primary breast tumours. Southern transfers of DNA from
representative tumours were hybridised with the pNR-2 probe
(upper panel) or tubulin probe (lower panel) as described in the
Materials and methods. The sizes of hybridising fragments are
shown on the right. Tumours 20 and 23-28 were primary ductal
carcinomas. Tumour 21 was a primary lobular carcinoma and 22
a primary colloid carcinoma.
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Figure 3 Correlation between oestrogen receptor mRNA and
pNR-2 RNA levels in primary breast tumours. RNA levels were
determined as described in the Materials and methods and are
plotted on a logarithmic scale. The RNA levels were compared
using Spearman's correlation coefficient, r, = 0.42, P<0.001,
n = 60.
(May & Westley, 1986). This pattern was found in all sam-
ples and there were no Eco R1 fragment length polymor-
phisms. The presence of pNR-2 gene amplification was
assessed by using a probe for the tubulin gene as described in
the Materials and methods. The mean ratios of pNR-2 to
tubulin was 0.7 (s.e.m. 0.034) and ratio ranged from 0.27 to
1.87. For most samples the value of the ratio was close to the
mean and it is therefore unlikely that significant gene
amplification could account for the large differences in levels
of pNR-2 RNA expression. Although this shows that the
pNR-2 gene is not highly amplified the possibility of small
(2-fold) differences in pNR-2 copy number cannot be ex-
cluded.
pNR-2 and oestrogen receptor RNA levels in ductal carcinomas
related to degree ofdifferentiation.
The 55 primary ductal carcinomas were graded with respect
to differentiation using the method of Bloom and Richardson
(1957). There were two grade 1, 22 grade 11, and 31 grade III
tumours. Thirty per cent of the better differentiated tumours
(grade 1/11) did not express the pNR-2 RNA, compared to
48% of the poorly differentiated tumours (grade III) (Figure
5). The median pNR-2 RNA levels of the better
differentiated tumours (grade l/II) and the poorly
differentiated tumours (grade III) were not significantly
different.
Median oestrogen receptor RNA levels were significantly
higher (P<0.05) in the better differentiated tumours (grade
I/II; median 14.83, range 0-242) than in the poorly
differentiated tumours (grade III; median 0, range 0-180).
All six tumours which did not contain oestrogen receptor
mRNA were grade III.
Relationship between menopausal status andpNR-2 or
oestrogen receptor RNA levels
Oestrogen receptor and pNR-2 mRNA levels were compared
in premenopausal (under 50 years old) and post-menopausal
(over 50 years old) women. Twenty-two of the 60 primary
tumours came from women aged less than 50 and 38 from
women aged over 50. The levels of the pNR-2 and oestrogen
receptor mRNAs in tumours from premenopausal and post-
menopausal patients are shown in Figure 6. The proportion
of tumours that expressed pNR-2 RNA from pre-
menopausal and from post-menopausal women was approx-
imately equal (41% and 46%) The median levels of both
pNR-2 mRNA and oestrogen receptor mRNA were not
significantly different.ER AND PNR-2 RNA LEVELS IN BREAST CANCER 35
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Figure 5 pNR-2 and oestrogen receptor mRNA levels in
primary breast carcinoma according to histological grade. The
histological grade of the tumours was determined according to
Bloom and Richardson (1957). The pNR-2 and oestrogen recep-
tor (ER) RNA levels are plotted on a logarithmic scale.
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Association between Iymph node metastasis and expression of
pNR-2 and oestrogen receptor mRNAs
The lymph node status was determined histologically for 47
of the 60 primary tumours. The levels of the pNR-2 and
oestrogen receptor RNAs from patients with and without
confirmed lymph node metastases are shown in Figure 7.
Sixty-seven per cent of tumours from patients with confirmed
lymph node metastases expressed pNR-2 RNA, whereas only
40% of tumours from patients without lymph node metastases
expressed pNR-2. However, the mean and median levels of
pNR-2 were not significantly different in tumours from
patients with and without confirmed lymph node metastases.
Oestrogen receptor RNA levels and the proportion of oest-
rogen receptor negative tumours were also similar in these two
groups of patients.
Expression ofoestrogen receptor andpNR-2 mRNAs in breast
cancer metastases
The levels of the pNR-2 and oestrogen receptor RNAs in
metastatic deposits are compared to those in primary
tumours in Figure 8. The levels of pNR-2 and oestrogen
receptor mRNA in primary tumours and metastatic deposits
were not statistically different.
pNR-2 and oestrogen receptor mRNA were measured in
both the primary tumour and axillary lymph node metastases
in 11 cases. In six cases, similar levels were present in the
primary tumour and the metastatic deposit. In one case, the
lymph node deposit contained both RNAs while the primary
tumour contained neither RNA and in two cases only oest-
rogen receptor mRNA was present in the primary tumour
and neither RNA was detectable in the metastatic deposit.
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Figure 6 pNR-2 and oestrogen receptor mRNA levels in
primary breast carcinoma according to menopausal status. The
pNR-2 and oestrogen receptor (ER) RNA levels are plotted on a
logarithmic scale for patients under (premenopausal) and over
(post-menopausal) 50 years of age.
pNR-2
0
0
0
to
1,
0
* 0
so
ih.i
ER
0
0
r
0
0
I
0
0
0
-ve +ve -ve +ve
Lymph node involvement
Figure 7 pNR-2 and oestrogen receptor mRNA levels in
primary breast carcinoma with or without lymph node involve-
ment. The pNR-2 and oestrogen receptor (ER) RNA levels are
plotted on a logarithmic scale.
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Figure 8 Comparison of pNR-2 and oestrogen receptor mRNA
levels in primary breast tumours and metastatic deposits in
involved lymph nodes. The pNR-2 and oestrogen receptor (ER)
levels are plotted on a logarithmic scale.
Expression ofoestrogen receptor andpNR-2 mRNAs in local
recurrences
Levels of the two mRNAs were measured in three samples
from tumours that had recurred locally in women who had
not received endocrine treatment. Two of these samples con-
tained both RNAs; in one instance the original tumour had
also been analysed and had expressed both RNAs. The third
was the only tumour in which the pNR-2 mRNA but not the
oestrogen receptor mRNA was detected; this tumour had
recurred in a patient who had received radiotherapy. One
local recurrence from a woman who had failed on endocrine
therapy did not contain either RNA; the primary tumour of
this patient had not expressed either RNA.
pNR-2 and oestrogen receptor RNA expression in breast
tumours ofpatients who have relapsed onfirst line tamoxifen
therapy
Elderly women increasingly receive tamoxifen as first line
therapy and the clincal response to tamoxifen is readily
assessed in this group of patients. Twenty-one tumour sam-
ples from patients receiving primary tamoxifen therapy were
analysed. The levels of the pNR-2 and oestrogen receptor
mRNAs in these tumours are shown in Figure 9. Ten
patients had shown an objective response to tamoxifen for
9-30 months but all had ultimately relapsed. A single patient
came to surgery despite a continued response to tamoxifen
therapy. Ten patients had shown no objective response to
tamoxifen despite treatment for 3-8 months.
A significantly higher proportion of tumours from patients
receiving primary tamoxifen did not contain pNR-2 and
oestrogen receptor mRNA (30% compared to 10% for un-
treated patients, P<0.05). There was no significant
difference in the proportion of either group expressing only
oestrogen receptor mRNA. Eight tumours expressed both
RNAs (Figure 9). Mean levels of pNR-2 in tumours from
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Figure 9 pNR-2 and oestrogen receptor mRNA levels in
tumours of patients receiving primary tamoxifen therapy. The
pNR-2 and oestrogen receptor mRNA levels are plotted for
tumours that showed complete or partial response to tamoxifen
(0 ), remained static (0 ) or did not respond (0 ). * shows the
pNR-2 and oestrogen receptor mRNA levels in a tumour that
showed continuing response at the time of resection.
patients who had received prior tamoxifen therapy did not
differ significantly from those of patients who had not. Mean
levels of oestrogen receptor mRNA were, however,
significantly lower in tumours from patients receiving
primary tamoxifen (6.88 units, s.e.m. 2.64) than in primary
tumours from post-menopausal women not receiving tamox-
ifen (37.33 units, s.e.m. 11.86, P<0.025).
A significantly higher proportion of tumours from the 11
patients who responded expressed pNR-2 than did tumours
from the 10 patients who did not respond (eight versus one,
X2= 6.08, P<0.025; Figure 9). In contrast, the presence of
oestrogen receptor mRNA showed no significant association
with previous tamoxifen response. Mean levels of oestrogen
receptor RNA were, however, significantly higher in the
group of tumours which had responded (12.78 units, s.e.m.
4.4) than in the group which had not (0.392 units,
P<0.025).
pNR-2 mRNA levels and response to postoperative tamoxifen
Fourteen patients received adjuvant tamoxifen post-
operatively and have remained well without evidence of
metastatic disease: as follow-up times range from 7 to 29
months, no analysis has been possible. A further 16 patients
received postoperative tamoxifen on relapse. Seven of these
patients have died from metastatic breast cancer without
reponding to tamoxifen and another seven are alive but have
metastatic disease that does not respond to tamoxifen
therapy; follow-up times range from 13 to 29 months. Only
two patients with metastatic disease have responded to
tamoxifen. Mean levels of pNR-2 mRNA (196.57 units,
s.e.m. 87.76) and oestrogen receptor mRNA (16.87 units,
s.e.m. 12.64) in tumours from the group of patients who
subsequently developed metastases which did not respond to
tamoxifen were not significantly lower than mean levels in
primary tumours from patients who did not receive tamox-
ifen at any stage (mean pNR-2 mRNA levels 394.16 units,
s.e.m. 149.19; mean oestrogen receptor mRNA levels, 34.73
units, s.e.m. 9.62) Over the limited follow-up period, pNR-2
levels did not appear to influence time to first relapse or
death.
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Discussion
The pNR-2/pS2 mRNA was discovered as a result of its
oestrogen regulation in human breast cancer cell lines
(Masiakowski et al., 1982; Prud'homme et al., 1985; May &
Westley, 1986). Its expression has also been detected in nor-
mal gastric mucosa where it is not regulated by oestrogens
(Rio et al., 1988) and in a proportion of breast tumours. As
it is not expressed at high levels in normal breast epithelial
cells (Zajchowski et al., 1988) and is expressed and regulated
by oestrogens in oestrogen responsive breast cancer cell lines,
it may be a useful marker of oestrogen response in breast
cancer. Two other groups have studied pNR-2/pS2 expres-
sion in surgically resected human breast tumours. Prud'
homme et al. (1985) detected pNR-2/pS2 expression in two
of seven breast cancer samples. More recently, expression of
pNR-2/pS2 and oestrogen receptor mRNA or protein has
been studied in a series of 180 breast cancer samples (Rio et
al., 1987); 48% of these tumours contained both pNR-2/pS2
mRNA and oestrogen receptor and 29% did not contain
either. In the present study, oestrogen receptor mRNA and
pNR-2 mRNA were found together in 54% of all tumour
samples and 17% of samples did not contain either. These
results are therefore similar to those of Rio et al. (1987). The
slightly higher proportion of tumours expressing both RNAs
could be due to differences in the population studied or may
reflect the greater sensitivity of the assay employed in the
present study (Henry et al., 1988). Rio et al. (1987) also
found a good correlation between pNR-2/pS2 mRNA levels
and positive immunohistochemical staining of breast tumours
using a polycloncal antibody to the pNR-2/pS2 protein
product.
In human breast cancer cells in vitro, pNR-2 is under strict
oestrogen regulation and is induced up to 100-fold by oest-
rogens (May & Westley, 1988). Our results suggest that
expression of the pNR-2 gene is under similar oestrogen
regulation in vivo. Only one of a total of 17 oestrogen
receptor mRNA negative tumour samples contained the
pNR-2 mRNA and this was a deposit of recurrent lobular
carcinoma from a patient who had previously received
radiotherapy. Although not all oestrogen receptor mRNA
positive tumours expressed the pNR-2 mRNA, a larger pro-
portion of those expressing higher levels of oestrogen mRNA
expressed pNR-2 mRNA. pNR-2 and oestrogen receptor
mRNA levels were significantly correlated for the 60 primary
tumours from patients not receiving tamoxifen. The
significance of this correlation, however, was dependent on
the tumours that were negative for both mRNAs; when the
group ofpNR-2 positive tumours was analysed in isolation the
correlation was not statistically significant. This is not surpris-
ing, as many factors other than hormone receptor concentra-
tion (e.g. varying endogenous levels of oestrogens, possible
interactions with other hormones and differences in the integ-
rity of the oestrogen response pathway) would be expected to
influence levels of pNR-2.
The elevated expression of the c-Erb B2 oncogene in a
proportion of breast tumours is frequently due to gene
amplification (Berger et al., 1988). To determine whether
high levels of pNR-2 expression are due to gene
amplification, the copy number of the pNR-2 gene was
analysed in 91 tumour samples. The results clearly showed
that there is no gross amplification of the pNR-2 gene and
therefore that the variation in pNR-2 mRNA levels probably
results from the regulation of its expression.
pNR-2 mRNA levels were not correlated with tumour
histology, differentiation or metastasis to axillary lymph
nodes. Oestrogen receptor levels are higher in better
differentiated tumours (McCarty et al., 1980) and it was
therefore possible that pNR-2 levels would show the same
pattern. In the series of tumours analysed in this study,
oestrogen receptor mRNA levels were significantly higher in
the better differentiated tumours and all the oestrogen recep-
tor mRNA negative tumours were grade III. pNR-2 mRNA
levels, however, were not higher in the better differentiated
group and there were not significantly more pNR-2 negative
tumours in the poorly differentiated group. The finding that
seven grade 1/II tumours were pNR-2 negative while none
were oestrogen receptor mRNA negative was of interest as it
might suggest that the capacity to express pNR-2 is lost at an
earlier stage in tumour de-differentiation.
There was a clear and highly significant association
between previous response to tamoxifen treatment and the
presence of pNR-2 mRNA in tumours of patients receiving
tamoxifen as primary endocrine therapy. Although the
measurements of pNR-2 were made following disease pro-
gression, this finding has implications for the value of pNR-2
as a predictive marker of response to tamoxifen in primary
breast cancer.
In addition, the high levels of pNR-2 mRNA expression in
tumours whose growth had been but is no longer inhibited by
tamoxifen has important implications for models of
tamoxifen resistance. The tumour levels of both oestrogen
receptor and pNR-2 mRNAs were no different in the patients
who had responded to and then relapsed on tamoxifen than
found in patients who had not received primary tamoxifen
therapy. This suggests that, in the majority of cases, relapse
is not associated with the outgrowth of oestrogen receptor
negative cells that are unresponsive to tamoxifen.
Experiments with tamoxifen-resistant oestrogen-responsive
cell lines have shown that tamoxifen resistance may be
associated with an increased agonist effect of tamoxifen on
cell proliferation (M.D. Johnson et al., in preparation) and
these data from patients receiving primary tamoxifen therapy
are consistent with this.
Two tumours did not contain oestrogen receptor mRNA
but had responded to tamoxifen. Their response is difficult to
rationalise but it is possible that these two tumours ceased to
respond to tamoxifen as a result of the outgrowth of oest-
rogen receptor negative cells.
There would be considerable clinical advantage in accurate
prediction of response to primary tamoxifen therapy using
the small amount of material provided by non-surgical diag-
nostic techniques such as fine needle aspiration or needle
biopsy. mRNA amplification techniques or immunohis-
tochemical staining for the pNR-2 protein product may per-
mit assay in such material, allowing assessment of pNR-2 as
a marker of anti-oestrogen response.
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